Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis
Authors:
- 21 July 2012
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 39 (5) , 479-498
Abstract
Our objective was to develop a beta regression (BR) model to describe the longitudinal progression of the 11 item Alzheimer’s disease (AD) assessment scale cognitive subscale (ADAS-cog) in AD patients in both natural history and randomized clinical trial settings, utilizing both individual patient and summary level literature data. Patient data from the coalition against major diseases database (3,223 patients), the Alzheimer’s disease neruroimaging initiative study database (186 patients), and summary data from 73 literature references (representing 17,235 patients) were fit to a BR drug-disease-trial model. Treatment effects for currently available acetyl cholinesterase inhibitors, longitudinal changes in disease severity, dropout rate, placebo effect, and factors influencing these parameters were estimated in the model. Based on predictive checks and external validation, an adequate BR meta-analysis model for ADAS-cog using both summary-level and patient-level data was developed. Baseline ADAS-cog was estimated from baseline MMSE score. Disease progression was dependent on time, ApoE4 status, age, and gender. Study drop out was a function of time, baseline age, and baseline MMSE. The use of the BR constrained simulations to the 0–70 range of the ADAS-cog, even when residuals were incorporated. The model allows for simultaneous fitting of summary and patient level data, allowing for integration of all information available. A further advantage of the BR model is that it constrains values to the range of the original instrument for simulation purposes, in contrast to methodologies that provide appropriate constraints only for conditional expectations.Keywords
This publication has 21 references indexed in Scilit:
- Missing Data in Model‐Based Pharmacometric Applications: Points to ConsiderThe Journal of Clinical Pharmacology, 2010
- How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGSStatistics in Medicine, 2005
- Multiple Imputation for Model Checking: Completed‐Data Plots with Missing and Latent DataBiometrics, 2005
- Beta Regression for Modelling Rates and ProportionsJournal of Applied Statistics, 2004
- Regression analysis of variates observed on (0, 1): percentages, proportions and fractionsStatistical Modelling, 2003
- An Object-Oriented Random-Number Package with Many Long Streams and SubstreamsOperations Research, 2002
- Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selectionJournal of Pharmacokinetics and Biopharmaceutics, 1994
- Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.Proceedings of the National Academy of Sciences, 1992
- Generalized Logistic ModelsJournal of the American Statistical Association, 1988
- Multivariate Correlation Models with Mixed Discrete and Continuous VariablesThe Annals of Mathematical Statistics, 1961